Chemical Linkers in Antibody-Drug Conjugates (ADCs)
Synaffix B.V. is pleased to announce the publication of “Chemical Linkers in Antibody-Drug Conjugates (ADCs)” published by Royal Society of Chemistry.
Third ADC with Synaffix’s Technology Enters Clinical Development
Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that its partner Shanghai Miracogen has commenced a Phase I trial in the US with MRG004A, an ADC designed to treat solid tumors. This is the 3rd ADC built with GlycoConnect™ ADC technology to enter the clinic.
PharmaCytics submitted 3 new patents
PharmaCytics has submitted 3 new patents to support their Nutrient Drug Conjugate-technology (NDCt). It shows the continuous commitment to develop our ground-breaking Nutrient Drug Conjugate technology. The patents cover new nutrient drug conjugates and new linker technologies. All patents will support the work of PharmaCytics ultimately benefiting patients by making drugs more effective.
PimBio: €0,5M for iPSC-based NMJ-on-a-chip model
PimBio is proud to announce that our NOACH (NMJ-On-A-CHip) consortium under the supervision of Dr. Maartje Huijbers has received a LUMC PPS-Match call Topsector LSH 2021 funding for the development of a patient-derived iPSC-based NMJs-on-a-chip model to study NMJ (patho)physiology by combining functional parameters with a relevant human genetic background.
In March 2021 we started with our exclusive vitality program: PiVitality, a course we developed together with FitNEZZplaza for our community members. Through the program we offer a variety of vitality-related activities and information focused on exercise, nutrition and mindfulness. The first group has now been working on the program for almost two months. We have already received positive reactions and have also integrated their valuable feedback for the second group. This way the program keeps getting a little better!
or call
Pivot Park – Building RK
Kloosterstraat 9
5349 AB Oss
The Netherlands
+31 (0)412 – 84 60 10
info@pivotpark.com
Pivot Park Exploitatie B.V.
Building OP
Kloosterstraat 9
5349 AB Oss
The Netherlands
10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.
We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.